FDA coverage on Peptide News Digest follows the agency's actual paper trail: approval letters, warning letters, PCAC meeting minutes, 503A bulks list rulings, draft guidance, and Citizen Petitions on substances ranging from semaglutide to BPC-157.
The center of gravity in 2025 and 2026 has been compounding. Once GLP-1 shortages resolved, the agency turned to enforcement — 503A patient-specific compounding versus 503B outsourcing, which APIs sit on which list, what counts as a 'clinical need,' and whether additive formulations count as new drugs. The April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list is the most consequential single move so far.
Outside GLP-1, the FDA has been active on peptide-vendor warning letters, advisory committee votes (PCAC, Endocrinologic and Metabolic Drugs), and the long grind of Section 503A's bulks list. Browse the latest below.
The two near-term peptide regulatory deadlines moved into the single-digit-week window on June 18. The FDA's April 30 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list closes its 60-day comment window on June 29, after which the agency will weigh comments and issue final rulemaking; once final, the rule blocks 503B outsourcing facilities from bulk-compounding the molecules even under future shortage designation. Separately, requests to make oral presentations at the July 23-24 PCAC peptide-compounding advisory committee close June 30; the committee will weigh BPC-157, KPV, TB-500, MOTs-c, DSIP (Emideltide), Semax, and Epitalon for 503A bulk-substances-list inclusion. Written PCAC comments remain open through July 9.
The FDA's April 30 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list enters its final two weeks of public comment on June 15. The 60-day comment window closes June 29, after which the agency will weigh comments and issue final rulemaking. Once finalized, the rule will prohibit 503B outsourcing facilities from bulk-compounding these GLP-1 molecules under any circumstance, including future shortage designation. The 503A pathway through licensed pharmacies remains intact ahead of the July 23-24 PCAC peptide-compounding advisory meeting, but the trajectory for large-scale GLP-1 compounding is fixed. Telehealth platforms (Hims & Hers, LifeMD, others) had already migrated to branded supply via Novo and Lilly partnerships since Q1 2026.
The Hill ran a Washington-policy framing of the July 23-24 PCAC peptide-compounding meeting, casting the agenda as the regulatory follow-through on HHS Secretary Robert F. Kennedy Jr.'s repeated pledges to ease access to wound-healing, weight-loss, and longevity peptides favored by the Make America Healthy Again movement. The committee will weigh BPC-157, KPV, TB-500, MOTs-c, DSIP (Emideltide), Semax, and Epitalon. Written comment closes July 9; oral-presentation requests close June 30, eighteen days from today.
The FDA's April 30 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulks list approaches its June 29 comment-window close. Once finalized, the rule effectively bars large-scale compounding of these GLP-1s under any clinical-need exception, accelerating the wind-down already underway among compounders (ProRx, BPI Labs, the Hims-affiliated manufacturer Medisource). Compounded GLP-1 telehealth platforms have largely pivoted to branded-drug fulfillment or microdose protocols, with the regulatory cliff at three weeks out.
With EASL and ASCO dominating the clinical-data cycle, the FDA peptide-compounding regulatory track continues moving toward the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting. Twelve peptides came off the FDA Category 2 'significant safety risk' bulks list effective April 23, 2026; seven of those (BPC-157, TB-500, KPV, MOTs-C on Day 1; Emideltide/DSIP, Semax, Epitalon on Day 2) advance to the July PCAC for affirmative 503A bulks-list inclusion. A second PCAC before end of February 2027 reviews five more (GHK-Cu injectable, Melanotan II, Cathelicidin LL-37, Dihexa, PEG-MGF). Removal from Category 2 does not yet permit compounding — that requires the affirmative PCAC recommendation plus FDA final determination (6-12 month timeline). The parallel 503B bulks-list proposal excluding semaglutide, tirzepatide, and liraglutide closes public comments June 29. The compounded-semaglutide shipment volume is down 90% year-over-year per the BSR Intelligence briefing as the regulatory vise tightens on the gray-market segment.
The FDA sent a warning letter to Harbin Jixianglong Biotech disclosed May 20 after inspectors discovered a compliance failure at the company's manufacturing facility two months after the firm had been added to the FDA's green list to export GLP-1 drugs to the US. Jixianglong allegedly bought semaglutide active pharmaceutical ingredient from a facility not on the green list, labeled the API as manufactured at its own plant (implying the green-listed origin), and shipped the batch to US customers. The FDA framed the labeling as an apparent attempt to circumvent import-alert safeguards. The agency's March 11 enforcement report had previously listed Jixianglong recalls of semaglutide for compounding use only, attributed to failing to complete process validation and bacterial endotoxin method validation before distribution. The action is part of the broader FDA Pharmaceutical Quality / GLP-1 supply-chain enforcement cycle, including the April 30 503B bulks-list proposal closing June 29.
The FDA confirmed the Pharmacy Compounding Advisory Committee will convene a second meeting before the end of February 2027 to review five additional peptides for potential 503A Bulk Drug Substances List inclusion: GHK-Cu (injectable formulation specifically — topical/cosmetic remains separate), Melanotan II, Cathelicidin (LL-37), Dihexa acetate, and Mechano Growth Factor Pegylated (PEG-MGF). The February 2027 meeting follows the July 23-24, 2026 PCAC that will review seven peptides (BPC-157, KPV, TB-500, MOTs-C on Day 1; Emideltide/DSIP, Semax, Epitalon on Day 2). Compounding pharmacies cannot legally compound these five peptides until the PCAC review concludes and the FDA issues a final determination — a 6-12 month timeline post-meeting. The peptide-specific indications under review span aesthetic dermatology (GHK-Cu, Melanotan II), antimicrobial activity (LL-37), neuroprotection (Dihexa), and growth-factor-mediated tissue regeneration (PEG-MGF).
The Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 — at which seven peptides (BPC-157, KPV, TB-500, MOTs-C on Day 1; Emideltide/DSIP, Semax, Epitalon on Day 2) will be discussed for 503A compounding inclusion — now has firm public-comment deadlines. Written submissions are due July 9, 2026 via regulations.gov; oral presentation requests close June 30, with the FDA allocating presentation slots after review. The PCAC review follows the April 23, 2026 effective date when 12 peptides came off the FDA's Category 2 bulks list. Industry stakeholders, patient groups, and clinicians are organizing through the SSRPi network and the Alliance for Pharmacy Compounding to coordinate testimony. The combined regulatory cycle — PCAC plus the parallel April 30 503B bulks-list proposal closing June 29 — will reshape the compounding-pharmacy economy through 2027 and determine which research peptides remain accessible through licensed channels.
The FDA announced an AI-Informed Inspection Pilot on May 15, 2026, applying machine-learning analysis to facility inspection prioritization and execution. The program is part of the FDA's Pharmaceutical Quality/Manufacturing Standards initiative and will affect peptide-manufacturing sites including 503A compounding pharmacies, 503B outsourcing facilities, and full-scale peptide CDMOs. AI inputs include historical inspection findings, FAERS adverse-event signals, supply-chain risk indicators, and recall history. The pilot lands during a sensitive compounding-pharmacy regulatory cycle ahead of the July 23-24 PCAC meeting on seven peptides for 503A bulks-list inclusion (BPC-157, KPV, TB-500, MOTs-C, Emideltide/DSIP, Semax, Epitalon) and against the April 30 503B bulks-list proposal closing comments June 29. Industry response is mixed: faster inspection cycles could ease compliance burden for well-run facilities but may concentrate enforcement on the gray-market segment.
The FDA updated its Section 503A bulks drug substances list on May 14, 2026, continuing the rolling-status changes leading into the July 23-24 PCAC meeting that will evaluate seven peptides (BPC-157, KPV, TB-500, MOTs-C on Day 1; Emideltide/DSIP, Semax, Epitalon on Day 2) for potential 503A-bulks-list inclusion. The April 30 503B bulks-list proposal (closing June 29) is moving in parallel toward effectively ending large-scale 503B compounding of semaglutide, tirzepatide, and liraglutide. The combined regulatory cycle through July 24 will reshape the compounding-pharmacy economy for the next 2-3 years and determine which research peptides remain accessible through licensed channels.
Hims & Hers reports Q1 2026 after market close May 11, with consensus revenue at $616-619M and EPS at roughly 3-4 cents — a 90% YoY decline. The investor question is whether the legitimate Wegovy/Ozempic distribution channel from the Novo Nordisk partnership (signed April 2026) can offset the wind-down of the compounded semaglutide business. Novo's branded products were not on the platform until March 26, with Q1 books closing March 31 — meaningful Wegovy revenue contribution likely lands in Q2. Subscriber count above 2.5M and ~82% three-month retention remain the standing benchmarks. The April 30 FDA proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list raises the medium-term bar for any compounding-driven model.
ITM Isotope Technologies Munich's Lu-edotreotide-177 (branded ITM-11), a peptide radioligand therapy targeting somatostatin receptor 2 (SSTR2) in gastroenteropancreatic neuroendocrine tumors, has an FDA decision goal of August 28, 2026. If approved, ITM-11 would expand US PRRT options beyond Novartis's Lutathera, which has held the SSTR2 PRRT category since 2018. Companion radiopharmaceutical kit Ga 68 edotreotide (LNTH-2501) supports PET imaging for SSTR-positive NETs. The August PDUFA sits alongside the July 23–24 PCAC meeting on seven 503A peptides and Roche's mid-2026 enicepatide+petrelintide combination Phase 2 start as the next-quarter peptide regulatory inflection points.
An FDA Adverse Event Reporting System (FAERS) entry logged April 30 surfaced publicly May 4, documenting hepatic failure in a 56-year-old male patient on Foundayo (orforglipron). The case was marked for expedited review and could have occurred at or before April 15 — Foundayo only launched April 9. There have been 34 total Foundayo FAERS reports so far, with two considered serious. LLY traded down nearly 3% premarket — hitting roughly $936 — before recovering on Lilly's response. Foundayo's label carries a warning that the medication is 'not recommended for use in patients with severe hepatic impairment' (orforglipron is primarily hepatically metabolized), but mild and moderate liver impairment is allowed at standard dose.
The Partnership for Safe Medicines issued a May statement strongly supporting the FDA's April 30 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulks list, citing 'sound science, sound law, and a clear-eyed commitment to patient safety.' The Partnership cited more than 455 adverse-event reports linked to compounded semaglutide and more than 320 tied to compounded tirzepatide — many involving dosing errors from multidose vials, some leading to hospitalization — as the safety basis. The group plans to submit a full comment to the Federal Register docket before the June 29 deadline and is encouraging other patient-safety groups to do the same.
Orrick published a May 2026 client memo walking through the FDA's April 30 proposal to formally exclude semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) from the 503B outsourcing-facility bulk drug substances list. The memo flags that the FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in February 2025, removing the two legal pathways that previously enabled large-scale compounding. Orrick advises weight-loss clinics, medical spas, and telehealth platforms still relying on compounded GLP-1 products to consult counsel ahead of the June 29 comment deadline.
The FDA's PCAC public docket FDA-2025-N-6895 is now accepting written comments on the proposed addition of seven peptides to the Section 503A bulk drug substances list ahead of the July 23–24 advisory committee meeting at White Oak. Day 1 will cover BPC-157, KPV, TB-500, and MOTs-C; Day 2 will cover Emideltide (DSIP), Semax, and Epitalon. Comments received by July 9 are guaranteed to be presented to the committee, and the docket closes July 22. The window gives compounders, prescribers, and patient advocates roughly twelve weeks to formally submit clinical evidence, pharmacovigilance data, and access arguments.
The FDA announced a proposal on April 30 to exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulks list, finding no clinical need for large-scale compounding now that branded supply has stabilized. Commissioner Marty Makary said outsourcing facilities cannot lawfully compound from bulk substances when FDA-approved drugs are available unless a clear clinical need exists. Public comments are open through June 29, 2026. The proposal targets 503B outsourcing facilities only and does not directly affect 503A patient-specific compounding, but it forecloses the largest legal pathway for branded-active GLP-1 compounding.
The FDA announced April 28 that it has completed first tests of a real-time data system that allows agency scientists to view safety and effectiveness data from clinical trial patients as it is collected — shifting from the traditional stop-and-go batch reporting model to a continuous live data stream. The pilot affects all therapeutic categories including peptide drugs, with implications for trial timelines, regulatory review speed, and adverse-event detection. Industry observers see the move as part of broader systemic agency change under the new HHS leadership.